Literature DB >> 7649495

Reduction of reperfusion injury of human myocardium by allopurinol: a clinical study.

J A Gimpel1, J R Lahpor, A J van der Molen, J Damen, J F Hitchcock.   

Abstract

To determine the possibility of myocardial protection against reperfusion injury by allopurinol, 22 aortocoronary bypass patients were studied. Eight patients received allopurinol (200 mg during induction of anesthesia and 100 mg after starting extracorporeal circulation) during surgery (group B), and 14 patients served as a control (group A). Blood samples and myocardial biopsies were taken before and 10 min after aortic cross-clamping. No statistically significant difference between the two groups was observed considering gender, age, prior myocardial infarction, left ventricular end diastolic pressure (LVEDP), and aortic cross-clamp time. Preservation of cardiac tissue was assessed by the measurement of quantitative birefringence (QBR) changes upon the addition of adenosine 5'-triphosphate (ATP) plus calcium in biopsies and the need for postoperative inotropes. The synthesis of peroxides was estimated by the measurement of leukotriene B4 and C4 (LTB4, LTC4). LTB4 was below the level of detection (< 1.5 ng/l) before and after cross-clamping in both groups, while the LTC4 level for group A increased from < 1.5 to 27 +/- 17 ng/l compared to an increase of < 1.5 to 11 +/- 8 ng/l for group B after 10 min of reperfusion (p = .036). The decrease in QBR value in group A was 1.26 +/- 0.28 and 0.35 +/- 0.23 for group B (p < .003). Postoperatively, 11 out of 14 patients in group A needed inotropic support (dopamine or dobutamine), whereas two patients out of eight did so in group B.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7649495     DOI: 10.1016/0891-5849(94)00242-c

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  12 in total

Review 1.  Xanthine oxido-reductase, free radicals and cardiovascular disease. A critical review.

Authors:  A M Robert; L Robert
Journal:  Pathol Oncol Res       Date:  2013-10-15       Impact factor: 3.201

Review 2.  Mechanisms of cell death in acute myocardial infarction: pathophysiological implications for treatment.

Authors:  C de Zwaan; M J A P Daemen; W Th Hermens
Journal:  Neth Heart J       Date:  2001-04       Impact factor: 2.380

3.  Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure?

Authors:  W Doehner; S D Anker
Journal:  Heart       Date:  2005-06       Impact factor: 5.994

4.  Uric acid and inflammatory markers.

Authors:  Carmelinda Ruggiero; Antonio Cherubini; Alessandro Ble; Angelo J G Bos; Marcello Maggio; Vishwa D Dixit; Fulvio Lauretani; Stefania Bandinelli; Umberto Senin; Luigi Ferrucci
Journal:  Eur Heart J       Date:  2006-04-12       Impact factor: 29.983

Review 5.  Oxidative risk for atherothrombotic cardiovascular disease.

Authors:  Jane A Leopold; Joseph Loscalzo
Journal:  Free Radic Biol Med       Date:  2009-09-12       Impact factor: 7.376

6.  Acrolein activates matrix metalloproteinases by increasing reactive oxygen species in macrophages.

Authors:  Timothy E O'Toole; Yu-Ting Zheng; Jason Hellmann; Daniel J Conklin; Oleg Barski; Aruni Bhatnagar
Journal:  Toxicol Appl Pharmacol       Date:  2009-02-07       Impact factor: 4.219

Review 7.  Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications.

Authors:  Cristine E Berry; Joshua M Hare
Journal:  J Physiol       Date:  2003-12-23       Impact factor: 5.182

8.  Cinnamaldehyde and allopurinol reduce fructose-induced cardiac inflammation and fibrosis by attenuating CD36-mediated TLR4/6-IRAK4/1 signaling to suppress NLRP3 inflammasome activation.

Authors:  Lin-Lin Kang; Dong-Mei Zhang; Chun-Hua Ma; Jian-Hua Zhang; Ke-Ke Jia; Jia-Hui Liu; Rong Wang; Ling-Dong Kong
Journal:  Sci Rep       Date:  2016-06-08       Impact factor: 4.379

9.  Divergence of mechanistic pathways mediating cardiovascular aging and developmental programming of cardiovascular disease.

Authors:  Beth J Allison; Joepe J Kaandorp; Andrew D Kane; Emily J Camm; Ciara Lusby; Christine M Cross; Rhianon Nevin-Dolan; Avnesh S Thakor; Jan B Derks; Jane L Tarry-Adkins; Susan E Ozanne; Dino A Giussani
Journal:  FASEB J       Date:  2016-03-01       Impact factor: 5.191

10.  Genetic Alterations in Oxidant and Anti-Oxidant Enzymes in the Vascular System.

Authors:  Maan A Awad; Sarah R Aldosari; M Ruhul Abid
Journal:  Front Cardiovasc Med       Date:  2018-08-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.